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The Future of Gene Patents and the Implications
for Medicine
On June 13, 2013, in Association for Molecular Pathology
v Myriad Genetics Inc, the US Supreme Court unani-
mously ruled that naturally occurring genes cannot be pat-
ented. Synthetic transcripts of genes, however, can be
patented.1 The case involved patent claims covering
BRCA1 and BRCA2; mutations in these genes are linked to
an increased risk for breast and ovarian cancer. Both sides
quickly claimed victory. Harry Osterer, MD, a clinician and
one of the plaintiffs, declared that the Court’s decision
would help society “feel more of the impact of the ge-
nomics revolution.”2 The Biotechnology Industry Orga-
nization claimed that the decision left intact patents on
the synthetic transcripts, “the commercially most impor-
tant form of DNA used in biotechnology.”3 On the day the
decision was announced, Myriad Genetics stock initially
jumped 12% but finished down 6%. So what does this de-
cision really mean, for both patent law and medicine?
The Myriad decision concerned one particular le-
gal doctrine in patent law, termed “patentable subject
matter” or “patent eligibility.” Simply put, a patent can
be granted only to someone who “invents or discovers”
a “new and useful process, machine, manufacture, or
composition of matter, or any new and useful improve-
ment thereof.”4 Historically, courts and the US Patent and
Trademark Office have interpreted these terms broadly
to encompass “anything under the sun made by man.”
This has not included “laws of nature,” “natural phenom-
ena,” “abstract ideas,” or “products of nature.”5 Yet, a fa-
mous 1911 lower court decision concluded that “prod-
ucts of nature” may constitute patentable subject matter
if they were “isolated and purif ied” from their
surroundings.6 Precisely what constitutes a “product of
nature,” or the propriety of this “isolated and purified”
exception, has long been a puzzle. Nonetheless, hu-
man genes have been eligible for patent protection since
at least 1982 under the theory that they were “isolated
and purified” from their surrounding chromosomes. The
Myriad case is the first time the Supreme Court ad-
dressed this practice.
In Myriad, the Court considered 2 types of patent
claims for human genes. The first type covered “iso-
lated genomic DNA,” that is, DNA fragments of various
sizes that have simply been removed from the surround-
ing genome. The second type were claims directed to
“complementary DNA” (cDNA), specifically, reverse tran-
scripts of messenger RNAs (mRNAs). The Court ruled
that claims on isolated genomic DNA were not patent eli-
gible—even if the genomic DNA were “isolated and pu-
rified” from the surrounding chromosome. Claims for
cDNA, however, were patent eligible.
The Court’s decision primarily focused on whether
either type of DNA existed as such in nature. Because the
Court viewed isolated genomic DNA as a stretch of DNA
simply excised from a larger chromosomal region, it con-
cluded this was more like a “product of nature” than “a
product of human ingenuity.”1 These DNAs did not have
“a distinctive name, character [and] use,” nor did they pos-
sess “markedly different characteristics from any found
in nature.”1 Although the Court was careful not to negate
Myriad’s work in sequencing the BRCA genes, it declared
that “separating [a] gene from its surrounding genetic ma-
terial is not an act of invention”1 and that “[g]roundbreak-
ing, innovative, or even brilliant discovery does not by it-
self satisfy”1 patent eligibility. Under these circumstances,
the Court was reluctant to extend the “isolated and pu-
rified” doctrine, despite its historical pedigree. There-
fore, claims on isolated genomic DNA are now patent in-
eligible because they are “products of nature.”1
But cDNA does not exist, as such, in nature. Even
though the “nucleotide sequence of cDNA is dictated by
nature,” in mRNA transcripts, “the lab technician un-
questionably creates something new when cDNA is
made,” according to the Court.1 Thus, claims on cDNA are
potentially patentable, although, as the Court noted,
other legal doctrines might still bar patenting of cDNA
sequences in some cases. For example, patents cover-
ing cDNA sequences, although eligible for patent pro-
tection, might still not be patentable, if obvious or if pre-
viously disclosed elsewhere.
One result of Myriad is fairly clear: testing for BRCA
genes should be cheaper. Within hours after the deci-
sion, several companies announced that they would of-
fer BRCA1 and BRCA2 testing for much less than Myri-
ad’s then-current prices. Myriad has charged as much as
$4100 for full-sequence testing; some competitors have
announced prices in the range of $1000 to $2200 for
the same level of testing. These price declines will prob-
ably stick. Because Myriad’s cDNA claims cover only test-
ing methods that require the creation of cDNA, other
companies will be able to compete with Myriad using
newer sequencing technology that does not involve
cDNA. (Myriad’s claims for the method of assessing
breast cancer risk based on BRCA1 and BRCA2 se-
quences were struck down at an earlier stage of the case.)
Myriad will likely lower its prices for BRCA testing as it
responds to the competition, although not without a
fight; on July 10, 2013, Myriad sued one of its new BRCA
testing competitors for patent infringement.
Yet, it remains to be seen just how much more
widely available BRCA testing will be. Although Myriad
no longer has a monopoly on sequencing the genes, it
does have an extensive—and exclusive—database of its
past customers’ mutations. That database may help
Myriad determine whether a patient with an unusual ge-
netic variation has a higher risk of cancer or not, al-
though patients with either wild-type BRCA sequences
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or well-known mutations will likely not need the added precision that
the database can provide. In addition, others are actively trying to
replicate Myriad’s database of mutations.
What the BRCA testing landscape would have looked like if the
Court had upheld all of Myriad’s patent claims is unclear. The now-
invalid claims for the most basic of Myriad’s patents would have ex-
pired in February 2016, and new testing technologies might have pro-
duced BRCA tests that would not have infringed on those patents
anyway.
What about the world beyond BRCA? Thousands of genes have
been patented, and thousands of genetic tests are available, but al-
most no genetic tests have caused patent controversies. For ex-
ample, the gene involved in Huntington disease, HTT, has long been
patented, but there have been few complaints about Huntington’s
testing because the patents were either not asserted or licensed non-
exclusively and on easy terms.7 The “gene patent problem” has been
almostentirelyaMyriadGeneticsproblem.Otherfirmsthatmighthave
been tempted to enforce their gene patents aggressively would have
confronted the same impending patent expirations and noninfring-
ing technological advances that Myriad faces now. Thus, although the
Court’s decision brings some reassurance to those worried that hun-
dreds of patents might be asserted against broad gene-sequencing
technologies, that risk never seemed great. The end of Myriad’s mo-
nopoly on BRCA testing is to be applauded, but the Court’s decision
is likely to have only have limited effects on genetic testing.
Will the Myriad decision chill investment in genetic research?
Probably not. Fewer and fewer researchers have been receiving pat-
ents for isolated genomic DNA sequences. Many gene researchers
are publicly funded, and many researchers are not substantially
motivated by the potential for profits. Synthetically created, novel,
nonobvious DNA sequences—important for purposes other than di-
agnostic testing, such as for creating recombinant biological prod-
ucts—are still eligible for patents, although it is not clear how impor-
tant those patents might be. Nonetheless, some interpretations of
the Court’s decision might chill pharmaceutical research. If, for ex-
ample, a drug company discovers a medically important molecule
naturally produced by a fungus, the decision might prohibit the firm
from patenting the molecule itself. But the company still should be
able to patent medicinal uses of that molecule, as well as useful varia-
tions made in a laboratory. And, if the company shepherds that new
chemical entity through FDA approval, the approval will include the
exclusive right to sell the drug for 5 years.
In fact, on July 2, 2013, public interest organizations filed their
brief in the appeal of their suit, Consumer Watchdog v WARF, to in-
validate claims to human embryonic stem cells in patents of the Wis-
consin Alumni Research Foundation. The appellate brief argues,
among many other things, that the cells are “products of nature” and
thus not patent eligible under the Myriad decision. It is not at all clear
that those arguments will prevail, but it is more evidence that the
decision will be good for the patent litigation business.
So what does the Myriad decision ultimately mean? In the short
term, it means more competitive markets for diagnostic genetic test-
ing, at least for testing for BRCA1 and 2. But in the long term, prob-
ably not very much.
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